ALS (ALQ) Investor Day 2025 summary

Strategic direction and future plans

• Refreshed global strategy targets mid to high single-digit organic growth, steady margins, and a minimum 15% ROCE, focusing on high-quality testing markets and disciplined capital allocation.

• Portfolio rationalisation has doubled revenue CAGR to 14% (FY21-25), with 90% of revenue in priority segments and increased exposure to Americas and Europe.

• M&A pipeline exceeds AUD 1.3 billion, with 140+ targets reviewed, prioritizing strategic fit and minimum ROCE, and recent successful integrations.

• Confirmed FY2027 targets of AUD 3.3 billion revenue, AUD 600 million EBIT, and a 19% margin floor, with a focus on ongoing profitable growth and market-leading returns.

• Strategy execution is guided by the 'Roadmap to Win,' aligning structure, culture, and technology for competitive advantage.

Digital transformation and innovation

• Digital transformation is central, with 78% of revenue on a unified LIMS platform and 200+ digital specialists supporting global operations.

• AI and automation initiatives have reduced unit costs by 30%, improved productivity by 15%, and delivered measurable impacts such as 40% work quality improvement and 138% consistency gains in mineral labs.

• Smart labs powered by robotics, AI, and data integration are being rolled out globally, with capital included in the AUD 230 million investment program.

• Digital client integration, such as the eCOC Loader, enhances data quality, workflow efficiency, and real-time decision-making.

• Mandatory AI training is being implemented for all employees, with intensive programs for over 100 leaders to drive sustainable adoption.

Business segment performance and growth opportunities

• Minerals division achieved 14% CAGR over four years, generating AUD 851 million in FY25, with growth from downstream services and data analytics.

• Environmental segment delivered AUD 1,120 million in FY25, with 17% revenue CAGR (FY22-25), market-leading PFAS testing, and expansion in Western Europe and the U.S.

• Life Sciences achieved ~20% revenue CAGR (FY21-25), contributing 27% of group revenue, with strong performance in food and environmental testing.

• Industrial Materials and Pharma are targeted for selective growth and operational optimisation, leveraging regional scale and cross-segment synergies.

• Global hub-and-spoke model and standardised systems drive operational excellence, scalability, and client-focused solutions.